Clinical trials: Infectious Panuveitis
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
- Trial name
- NEPTUNE (NCT05523765)
- Testing
- Brepocitinib
- Where
- 15 sites in United States
- Volunteers
- 26 people
- Sponsor
- Priovant Therapeutics, Inc.
Uveitis
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
- Trial name
- Visual II (NCT01124838)
- Testing
- Adalimumab, Prednisone
- Volunteers
- 261 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Uveitis, Intermediate Uveitis
Sirolimus as Therapeutic Approach to Uveitis
The purpose of this study is to find out about the safety and effectiveness of the study drug, sirolimus, in patients with uveitis and to utilize the potential effectiveness of sirolimus, and yet to avoid the potential…
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- SAVE (NCT00908466)
- Testing
- Sirolimus (rapamycin)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Uveitis
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.
- Trial name
- EYEGUARD™-C (NCT01747538)
- Testing
- Dose 1 gevokizumab, Dose 2 gevokizumab
- Where
- 115 sites in United States, Argentina and 20 more
- Volunteers
- 281 people
- Sponsor
- XOMA (US) LLC
Noninfectious Posterior Uveitis, Uveitis, Posterior
Frequency and Intensity of Inflammatory Relapses in Patients With Non-infectious Posterior Uveitis Treated With a Fluocinolone Acetonide Implant
Non-infectious posterior uveitis is a chronic inflammatory eye disease that can lead to irreversible retinal damage and visual impairment due to repeated inflammatory relapses.
- Conditions
- Noninfectious Posterior Uveitis, Uveitis, Posterior, Uveitic Macular Edema
- Trial name
- FIRE (NCT07423442)
- Testing
- fluocinolone acetonide intravitreal implant
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Nantes University Hospital
Uveitis
Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis
The aim of this study is to determine the efficacy and safety of ADA plus MTX for the treatment in non-infectious pediatric panuveitis.
- Trial name
- NCT04588818
- Testing
- Adalimumab plus Methotrexate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Uveitis Posterior Non-Infectious, Inflammation Eye
Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles
This multicenter, prospective, interventional, non-pharmacological study aims to investigate whether the intraocular cytokine profile is associated with the therapeutic response to immunosuppressive drugs in patients with…
- Conditions
- Uveitis Posterior Non-Infectious, Inflammation Eye, Uveitis, Uveitis, Anterior
- Trial name
- PRIN_NIU (NCT07262437)
- Testing
- to improve clinical practice in treatment of non-infective uveitis
- Where
- 3 sites in Italy
- Volunteers
- 220 people
- Sponsor
- University of Milan
Intermediate Uveitis, Posterior Uveitis
Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study
In the STOP-UVEITIS study, we propose to evaluate the safety, tolerability, and bioactivity of two doses of Tocilizumab (4mg/kg and 8mg/kg), administered monthly, in patients with non-infectious intermediate, posterior, or…
- Conditions
- Intermediate Uveitis, Posterior Uveitis, Pan-uveitis
- Trial name
- STOP-Uveitis (NCT01717170)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Nebraska
Uveitis, Anterior, Panuveitis
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
- Trial name
- LUMINATE (NCT00404885)
- Testing
- LX211
- Where
- 30 sites in United States, Austria and 5 more
- Volunteers
- 108 people
- Sponsor
- Lux Biosciences, Inc.
Uveitis, Posterior Uveitis
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
The purpose of this study is to assess the safety, tolerability, and efficacy of AEB071 as a therapy for uveitis. Vision improvement and reduction in the swelling of retina will be measured for the assessment of efficacy.
- Conditions
- Uveitis, Posterior Uveitis, Panuveitis
- Trial name
- NCT00615693
- Testing
- AEB071
- Where
- 13 sites in United States
- Volunteers
- 13 people
- Sponsor
- Novartis
Chronic Uveitis
Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)
The objective of this study is to evaluate long-term safety of gevokizumab in patient with chronic non-infectious uveitis who previously well tolerated the study drug and may benefit from longterm treatment with gevokizumab.
- Trial name
- EYEGUARD-X (NCT02375685)
- Testing
- Gevokizumab
- Where
- 13 sites in Australia, Austria and 11 more
- Volunteers
- 71 people
- Sponsor
- Institut de Recherches Internationales Servier
Uveitis
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
A study comparing the safety and efficacy of adalimumab compared with placebo in patients with active uveitis.
- Trial name
- VISUAL l (NCT01138657)
- Testing
- Adalimumab, Prednisone
- Volunteers
- 239 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection
Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis
Toxoplasmosis affects one to two newborn each 10000 births. Among them, 1 to 2 % develop learning disabilities or die, and 4 to 27 % develop a chorioretinitis sometimes leading to an amblyopia responsible for visual impairment.
- Trial name
- BIOLUVE (NCT02843438)
- Testing
- Fluorescein angiography, Dilated fundus examination, Toxoplasmosis serology
- Where
- France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Grenoble
Uveitis, Uveitis, Posterior
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
The study is designed to evaluate the safety and efficacy of suprachoroidally administered triamcinolone acetonide, CLS-TA, in subjects with macular edema associated with non-infectious uveitis.
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Trial name
- PEACHTREE (NCT02595398)
- Testing
- 4mg CLS-TA Suprachoriodal Injection
- Where
- 64 sites in United States, India and 1 more
- Volunteers
- 160 people
- Sponsor
- Clearside Biomedical, Inc.
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404612)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 218 people
- Sponsor
- Lux Biosciences, Inc.